- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00590083
Administration of Virus-Specific Cytotoxic T-Lymphocytes (LYPTAIST)
Administration of Virus-Specific Cytotoxic T-Lymphocytes for the Prophylaxis and Therapy of Adenovirus Infection Post Allogeneic Stem Cell Transplant
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Viral infection is one of the major causes of morbidity and mortality in patients who receive bone marrow transplantation (BMT) from unrelated or mismatched donors. This increased risk of infection relates to a number of factors including the immunosuppressive regimens these patients receive, delayed immune recovery and the greater genetic disparity between donor and recipient that result in defective interactions between antigen presenting cells and immune system effector cells. In most cases viral infection post BMT results from reactivation of latent virus and CMV, EBV and adenoviruses (Ad) are the commonest viral pathogens causing disease after transplant.
The incidence of Ad infection is >25% for patients at risk in the first 100 days after transplant 1 2. In the transplant population, adenovirus is recoverable from many sites and may cause hemorrhagic cystitis, pneumonitis, nephritis, hepatitis, colitis and pancreatitis, often with severe morbidity and a mortality approaching 60%3. The most frequently used drug for the treatment of adenoviral infections is Cidofovir. But while there are occasional reports of responses to Cidofovir, no approved antiviral agent has proven efficacy for the treatment of severe Ad disease, nor are there any prospective randomized, controlled trials of potentially useful anti-Ad therapies 4. With the increasing use of so-called submyeloablative or reduced intensity, highly immunosuppressive conditioning regimens, higher rates of Ad infections/reactivation have been observed due to prolonged immune suppression. The onset of Ad disease/reactivation has recently been reported to occur at a median of 18 days post-transplant (range -7/>+100) 2.
As viral complications in these patients are clearly associated with the lack of recovery of virus-specific cellular immune responses, reconstitution of the host with in vitro expanded CTLs is an effective approach to prevent and treat these diseases. Adoptive immunotherapy with in vitro expanded CTLs has proved effective in preventing and treating diseases related to Epstein Barr virus (EBV) infections 5; 6 and cytomegalovirus (CMV) reactivations7 in hematopoietic stem cell transplant (HSCT) recipients. A promising strategy to generate donor-derived Ad-specific CTL is the infection of monocytes that direct the CTL response to viral capsid antigens8. This approach allows exposure to all proteins in the Ad protein coat, leading to presentation of multiple, undefined antigen epitopes. Hence, the investigators now plan to use a recombinant Ad vector for infection of donor-derived monocytes. These infected monocytes will then be used as antigen presenting cells (APC) to generate Ad-specific CTL in vitro. For the expansion of the Ad-specific CTL, the second stimulation will use irradiated, Ad-infected monocytes and subsequent stimulations will use donor-derived Lymphoblastoid Cell Lines (LCL) transduced with the Ad vector as an APC 9.
The investigators propose to evaluate this approach for the prophylaxis of Ad reactivation and disease in the recipients of matched unrelated donor or mismatched family member bone marrow allografts, who are at high risk for this complication. Initially, the investigators will give the donor-derived Ad-specific CTLs to patients in a dose escalation study to determine their safety and immunologic and virologic efficacy.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20894
- National Institute of Health (NIH)
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recipients of allogeneic (i.e. HLA matched or mismatched related or unrelated) donor stem cell transplants at risk for Adenoviral disease
- No evidence of GVHD > Grade II at time of enrollment
- Life expectancy > 30 days
- No severe intercurrent infections
- Lansky/Karnofsky scores >60
- Absence of severe renal disease (Creatinine > x 3 normal for age)
- Absence of severe hepatic disease (direct bilirubin > 3 mg/dl or SGOT > 500)
- Patient must be at least 30 days post transplant to be eligible to receive CTL
- Not receiving Cidofovir
- Patient has not received other viral specific CTL prophylactically within 4 weeks of receiving Adv-CTL
- Patient/guardian able to give informed consent
Exclusion Criteria:
- Patients with GVHD Grades III-IV
- Patients with hepatic or renal disease as specific above
- Patient has received other viral specific CTL (e.g. EBV-specific CTL or CMV-specific CTL) within 4 weeks of receiving Adv-CTL
- Patients with Adenoviral disease prior to day +30 post transplant Adenoviral diseases defined as the presence of more than two sites positive for adenovirus by culture
- Patients with less than 50% donor chimerism in either peripheral blood or bone marrow or patients with relapse of original disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Virus Specific Cytoxic T lymphocytes
|
Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant. One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety, toxicity and MTD of 1 IV injection of donor-derived adenovirus-specific CTLs given as adenovirus prophylaxis to patients at risk of developing adenovirus infection after allogeneic stem cell transplant.
Time Frame: 1 year
|
1 year
|
To evaluate the recovery of virus-specific immunity after CTL infusion and assess its correlation with protection from viral load and disease.
Time Frame: 1 year
|
1 year
|
To obtain preliminary information regarding whether the presence of antigen is required for Ad-specific CTL persistence in vivo.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Catherine Bollard, MD, Baylor College of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14097-LYPTAIST
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenovirus Infection
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...WithdrawnAdenovirus InfectionUnited States
-
Central Hospital, Nancy, FranceCompleted
-
ChimerixCompleted
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedCytomegalovirus Infection | Adenovirus InfectionUnited States
-
Children's National Research InstituteM.D. Anderson Cancer CenterCompleted
-
St. Anna KinderkrebsforschungWithdrawnCytomegalovirus Infection | Adenovirus InfectionAustria
-
Baylor College of MedicineM.D. Anderson Cancer Center; Massachusetts General Hospital; National Heart,... and other collaboratorsCompletedEBV Infection | Adenovirus InfectionUnited States
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...Completed
-
Assistance Publique - Hôpitaux de ParisCompletedCytomegalovirus Infections | Adenovirus InfectionsFrance
-
Mari DallasRecruitingAllogeneic Hematopoietic Stem Cell TransplantationUnited States
Clinical Trials on CTL administration
-
University of SydneyUnknown
-
Beijing Doing Biomedical Co., Ltd.Unknown
-
New York Medical CollegeJohns Hopkins University; Children's Hospital of Philadelphia; Medical College... and other collaboratorsRecruitingPrimary Immune Deficiency Disorder | Viral InfectionUnited States
-
M.D. Anderson Cancer CenterWithdrawn
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI); The Methodist Hospital Research... and other collaboratorsCompletedCytomegalovirus InfectionsUnited States
-
Shixiu WuUnknownDigestive System Diseases | Esophageal Neoplasms | Esophageal DiseasesChina
-
Queen's UniversityCompletedMitochondrial BiogenesisCanada
-
Catherine BollardActive, not recruiting
-
Nantes University HospitalTerminatedSerologically Active Adult Systemic Lupus ErythematosusFrance
-
Nantes University HospitalUnknown